KEIO RESEARCHERS INFORMATION SYSTEM

Career 【 Display / hide 】

Career 【 Display / hide 】

• 2020.04

  -

  2022.03

  Keio University, School of Medicine Department of Internal Medicine (Nephrology, Endocrinology and Metabolism), Assistant Professor

• 2022.04

  -

  Present

  Keio University, School of Medicine Department of Internal Medicine (Nephrology, Endocrinology and Metabolism), Project Assistant Professor

Academic Background 【 Display / hide 】

Academic Background 【 Display / hide 】

• 2000.04

  -

  2006.03

  灘中学校・灘高等学校

• 2006.04

  -

  2012.03

  Keio University, School of Medicine

• 2016.04

  -

  2020.03

  Keio University, School of Medicine, 医学研究科博士課程（内科専攻）

Research Areas 【 Display / hide 】

Research Areas 【 Display / hide 】

• Life Science / Nephrology

• Life Science / Rehabilitation science

Books 【 Display / hide 】

Books 【 Display / hide 】

• イラストでわかる腎臓・透析療法・透析患者の体

  花房, 規男, メディカ出版, 2021.12,  Page： 270p

  Scope: 腹膜透析の種類

• 血液透析診療指針

  岡田, 一義, 井上, 朋子, 島, 久登, 田代, 学(腎臓内科医), 水口, 潤, 東京医学社, 2021.06,  Page： xvii, 364p

  Scope: ビタミン

• エビデンスに基づく多発性囊胞腎(PKD)診療ガイドライン

  厚生労働科学研究費補助金難治性疾患等政策研究事業(難治性疾患政策研究事業)難治性腎障害に関する調査研究班, 成田, 一衛, 東京医学社, 2020.08,  Page： xi, 92p

  Scope: 1 進行を抑制する治療 1）降圧療法

• 臨床検査法提要

  奥村, 伸生, 金井, 正光, 戸塚, 実, 本田, 孝行, 矢冨, 裕, 金原出版, 2020.05,  Page： 2012p

  Scope: 腹膜透析

• 腹膜透析診療指針

  岡田, 一義, 橋本, 寛文, 水口, 潤, 東京医学社, 2019.07,  Page： ix, 165p

  Scope: カテーテルトラブル診療指針

display all >>

Papers 【 Display / hide 】

Papers 【 Display / hide 】

• High body mass index is a risk factor for transition to hemodialysis or hybrid therapy and peritoneal dialysis-related infection in Japanese patients undergoing peritoneal dialysis

  Eriko Yoshida Hama, Kiyotaka Uchiyama, Tomoki Nagasaka, Ei Kusahana, Takashin Nakayama, Itaru Yasuda, Kohkichi Morimoto, Naoki Washida, Hiroshi Itoh

  International Urology and Nephrology （Springer Science and Business Media LLC)   2022.06

  Corresponding author, Accepted

  • Access to Document (DOI)

• Health-Related Quality of Life Sleep Score Predicts Transfer to Hemodialysis among Patients on Peritoneal Dialysis

  Tomoki Nagasaka, Naoki Washida, Kiyotaka Uchiyama, Eriko Yoshida Hama, Ei Kusahana, Takashin Nakayama, Itaru Yasuda, Kohkichi Morimoto, Hiroshi Itoh

  Healthcare （MDPI AG)  10 （ 6 ） 1030 - 1030 2022.06

  Corresponding author

  　View Summary

  Despite the superiority of peritoneal dialysis (PD) over hemodialysis (HD) regarding health-related quality of life (HRQOL), the specific HRQOL domain(s) that predict unplanned HD transfer remains uncertain. In this cohort study, we assessed the HRQOL of 50 outpatients undergoing PD using the Japanese version 1.3 Kidney Disease Quality of Life-Short Form from March 2017 to March 2018 and prospectively analyzed the association of each HRQOL component with HD transfer until June 2021. During the follow-up (41.5 (13.0–50.1) months), 21 patients were transferred to HD. In a multivariate Cox proportional hazards model adjusted for age, sex, PD vintage, urine output, Charlson comorbidity index, and incremental shuttle walking test, a higher sleep score was significantly associated with lower HD transfer rates (HR 0.70 per 10, p = 0.01). An adjusted subdistribution hazard model where elected transition to HD, death, and transplantation were considered competing events of unintended HD transfer that showed sleep score as an exclusive predictor of HD transfer (HR 0.70 per 10, p = 0.002). Our results suggest that sleep score among the HRQOL subscales is instrumental in predicting HD transfer in patients undergoing PD.

  • Access to Document (DOI)

• Development of Alveolar Hemorrhage After Pfizer-BioNTech COVID-19 mRNA Vaccination in a Patient With Renal-Limited Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Case Report

  Ken Nishioka, Shintaro Yamaguchi, Itaru Yasuda, Norifumi Yoshimoto, Daiki Kojima, Kenji Kaneko, Mitsuhiro Aso, Tomoki Nagasaka, Eriko Yoshida, Kiyotaka Uchiyama, Takaya Tajima, Jun Yoshino, Tadashi Yoshida, Takeshi Kanda, Hiroshi Itoh

  Frontiers in Medicine （Frontiers Media SA)  9 2022.04

  　View Summary

  Since the coronavirus disease 2019 (COVID-19) pandemic continues and a new variant of the virus has emerged, the COVID-19 vaccination campaign has progressed. Rare but severe adverse outcomes of COVID-19 vaccination such as anaphylaxis and myocarditis have begun to be noticed. Of note, several cases of new-onset antineutrophil cytoplasmic antibody-associated vasculitis (AAV) after COVID-19 mRNA vaccination have been reported. However, relapse of AAV in remission has not been recognized enough as an adverse outcome of COVID-19 vaccination. We report, to our knowledge, a first case of renal-limited AAV in remission using every 6-month rituximab administration that relapsed with pulmonary hemorrhage, but not glomerulonephritis, following the first dose of the Pfizer-BioNTech COVID-19 vaccine. The patient received the COVID-19 vaccine more than 6 months after the last dose of rituximab according to the recommendations. However, his CD19⁺ B cell counts were found to be increased after admission, indicating that our case might have been prone to relapse after COVID-19 vaccination. Although our case cannot establish causality between AAV relapse and COVID-19 mRNA vaccination, a high level of clinical vigilance for relapse of AAV especially in patients undergoing rituximab maintenance therapy following COVID-19 vaccination should be maintained. Furthermore, elapsed time between rituximab administration and COVID-19 mRNA vaccination should be carefully adjusted based on AAV disease-activity.

  • Access to Document (DOI)

• Effects of a remote patient monitoring system for patients on automated peritoneal dialysis: a randomized crossover controlled trial

  Kiyotaka Uchiyama, Kohkichi Morimoto, Naoki Washida, Ei Kusahana, Takashin Nakayama, Tomoaki Itoh, Takahiro Kasai, Shu Wakino, Hiroshi Itoh

  International Urology and Nephrology （Springer Science and Business Media LLC)   2022.04

  Lead author, Accepted,  ISSN  03011623

  　View Summary

  Purpose: Remote patient monitoring (RPM) has contributed to improved patient-centered outcomes and prognosis in patients with end-stage renal disease on automated peritoneal dialysis (APD). However, evidence from prospective trials is lacking. Methods: The participants (n = 15; median age: 65 years; males: 10; peritoneal dialysis vintage: 6.4 ± 3.5 years) randomly received APD therapy using the Kaguya® APD system either with or without the connective use of the cloud-based RPM software Sharesource® for 12 weeks. The primary outcome was patient satisfaction assessed using a modified nine-item Treatment Satisfaction Questionnaire for Medication (TSQM-9) questionnaire. The secondary outcomes were healthcare resource consumption, the health-related quality of life (HRQOL) subscales assessed with the Kidney Disease Quality of Life-Short Form questionnaire, and clinical laboratory parameters. Results: Significant improvements were observed in the TSQM-9 subscales of Effectiveness (64.4 ± 18.8 vs. 57.8 ± 18.8; P = 0.006) and Convenience (76.3 ± 15.4 vs. 63.3 ± 17.3; P < 0.001) in patients on Sharesource®. Moreover, Sharesource® reduced the total amount of healthcare resource consumption (0.80 ± 1.32 vs. 1.87 ± 2.39 times/12 weeks; P = 0.02) and consultation time during regular monthly visits (813 ± 269 vs. 1024 ± 292 s; P < 0.001). A significant increase in ultrafiltration volume was found associated with more frequent modification of APD prescription in patients with Sharesource®. Sharesource® also improved the HRQOL subscale of General Health and Vitality. Conclusion: Sharesource® can improve patient-centered outcomes in patients on APD while reducing the treatment burden for both patients and medical staff. Trial registration: The study was registered in the Japan Registry of Clinical Trials (jRCT Number: jRCTs032190005).

  • Access to Document (DOI)

• Serum thymus and activation-regulated chemokine level is associated with the severity of chronic kidney disease-associated pruritus in patients undergoing peritoneal dialysis

  Takashin Nakayama, Kohkichi Morimoto, Kiyotaka Uchiyama, Ei Kusahana, Naoki Washida, Tatsuhiko Azegami, Takeshi Kanda, Tadashi Yoshida, Hiroshi Itoh

  Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis （SAGE Publications)     089686082210854 - 089686082210854 2022.03

  Accepted,  ISSN  0896-8608

  　View Summary

  Background:
  
  Thymus and activation-regulated chemokine (TARC), which induces a Th2-dominated inflammation, is a well-known biomarker that reflects the severity of atopic dermatitis. The present study aimed to evaluate TARC as a Th2-associated marker with chronic kidney disease-associated pruritus (CKD-aP) in patients with peritoneal dialysis (PD).
  
  Methods:
  
  This single-centre cross-sectional study included patients who underwent PD in our hospital between August 2020 and July 2021. The severity and impaired quality of life (QOL) of CKD-aP were assessed using the visual analogue scale (VAS) and Japanese version of the 5-D itch scale (5D-J), respectively.
  
  Results:
  
  A total of 48 patients with PD were included in the present study. Age and dialysis vintage were (mean ± SD) 64.8 ± 12.0 year and (median (IQR)) 38.5 (11.5–91.5) month, respectively. VAS and 5D-J scores were 3.3 ± 2.0 and 10.5 (9.0–12.0), respectively. Serum TARC level was 481.5 (278.9–603.4) pg/mL (upper limits of normal 450 pg/mL) and significantly correlated with VAS ( r = 0.39, p = 0.006) and 5D-J score ( r = 0.37, p = 0.009). Multivariate linear analysis revealed that higher serum TARC level was significantly associated with VAS ( p &lt; 0.001) and 5D-J score ( p &lt; 0.001). Furthermore, the serum brain natriuretic peptide level tended to be associated with VAS ( p = 0.060) and 5D-J score ( p = 0.029).
  
  Conclusion:
  
  Serum TARC level is an independent predictor of the severity and impaired QOL of CKD-aP in patients with PD, and TARC might be involved in the pathogenesis of CKD-aP.

  • Access to Document (DOI)

display all >>

Reviews, Commentaries, etc. 【 Display / hide 】

Reviews, Commentaries, etc. 【 Display / hide 】

• ADPKDの治療：②非薬物治療（生活指導を中心に）

  内山 清貴

  腎臓内科 14 ( 5 ) 545 - 551 2021.11

  Lead author

• 長期腹膜透析患者における、継続した腎代替療法選択の結果としての生体腎移植

  内山 清貴, 楊井 朱音, 北山 千草, 坂口 隆志, 高上 紀之, 小野 慶介, 前田 啓造, 上條 由佳, 栁 麻衣, 石橋 由孝

  腎と透析 腹膜透析2019 87巻別冊   176 - 177 2019.11

  Lead author

• 長期腹膜透析後、生体腎移植を施行した高安動脈炎の一例

  楊井 朱音, 内山 清貴, 北山 千草, 坂口 隆志, 高上 紀之, 小野 慶介, 前田 啓造, 上條 由佳, 栁 麻衣, 石橋 由孝

  腎と透析 腹膜透析2019 87巻別冊   204 - 205 2019.11

• 高血圧症の予防と非薬物療法

  楊井 朱音, 内山 清貴, 石橋 由孝

  medicina 特集 外来診療必読エビデンス—日米比較で考える内科Standards of Excellence 54 ( 7 ) 1016 - 1019 2017.06

• 腹膜透析患者の感染症

  内山 清貴, 上條 由佳, 石橋 由孝

  腎臓内科・泌尿器科 特集 腎尿路と感染症 2 ( 5 ) 467 - 475 2015.11

  Lead author

display all >>

Awards 【 Display / hide 】

Awards 【 Display / hide 】

• Young Investigator Award

  2022.06, Japanese Society of Anti-Aging Medicine, 慢性腎臓病における運動耐用能低下の意義および運動療法の有用性についての検討

• Young Investigator Award

  2022.06, Keio University School of Medicine Alumni Association (Sanshikai), Home-based aerobic exercise and resistance training for severe chronic kidney disease: a randomized controlled trial

• 優秀演題賞

  2019.06, 日本抗加齢医学会

• YIA 会長賞（最優秀賞）

  2019.03, 日本腎臓リハビリテーション学会

• 優秀演題（医師部門臨床研究）

  2018.10, 日本腹膜透析医学会

display all >>